The present study supports the premise that the tumor inhibitory effects of EP54 are due to immunoregulatory mechanisms, with EP54-treated mice showing increased tumor infiltration by T lymphocytes, in particular CD4+ T cell subsets, Th1 and Th17. This evidence concerns the gene CD4 and neoplasm.